JP4201313B2 - 有害物質結合アルブミン除去システム - Google Patents
有害物質結合アルブミン除去システム Download PDFInfo
- Publication number
- JP4201313B2 JP4201313B2 JP2002109647A JP2002109647A JP4201313B2 JP 4201313 B2 JP4201313 B2 JP 4201313B2 JP 2002109647 A JP2002109647 A JP 2002109647A JP 2002109647 A JP2002109647 A JP 2002109647A JP 4201313 B2 JP4201313 B2 JP 4201313B2
- Authority
- JP
- Japan
- Prior art keywords
- albumin
- harmful substance
- bound
- bound albumin
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010088751 Albumins Proteins 0.000 title description 124
- 102000009027 Albumins Human genes 0.000 title description 124
- 239000003440 toxic substance Substances 0.000 title description 10
- 231100000167 toxic agent Toxicity 0.000 title description 9
- 239000000126 substance Substances 0.000 description 94
- 230000009931 harmful effect Effects 0.000 description 72
- 239000008280 blood Substances 0.000 description 35
- 210000004369 blood Anatomy 0.000 description 35
- 239000012528 membrane Substances 0.000 description 32
- 210000001124 body fluid Anatomy 0.000 description 18
- 238000009563 continuous hemofiltration Methods 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 230000004087 circulation Effects 0.000 description 17
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 16
- 239000010839 body fluid Substances 0.000 description 16
- 239000003463 adsorbent Substances 0.000 description 15
- 208000006454 hepatitis Diseases 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 238000000502 dialysis Methods 0.000 description 14
- 238000011282 treatment Methods 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 238000001914 filtration Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000003792 electrolyte Substances 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 108010049003 Fibrinogen Proteins 0.000 description 8
- 102000008946 Fibrinogen Human genes 0.000 description 8
- 206010019663 Hepatic failure Diseases 0.000 description 8
- 229940012952 fibrinogen Drugs 0.000 description 8
- 208000019423 liver disease Diseases 0.000 description 8
- 208000007903 liver failure Diseases 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 238000007873 sieving Methods 0.000 description 8
- 206010008909 Chronic Hepatitis Diseases 0.000 description 7
- 239000012510 hollow fiber Substances 0.000 description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 6
- 231100000354 acute hepatitis Toxicity 0.000 description 6
- 231100000836 acute liver failure Toxicity 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 5
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000385 dialysis solution Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229960002319 barbital Drugs 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 229940019700 blood coagulation factors Drugs 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 101710153591 Albumin B Proteins 0.000 description 1
- 229920001747 Cellulose diacetate Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 102000002261 High-Molecular-Weight Kininogen Human genes 0.000 description 1
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 229960000510 ammonia Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ZURAKLKIKYCUJU-UHFFFAOYSA-N copper;azane Chemical compound N.[Cu+2] ZURAKLKIKYCUJU-UHFFFAOYSA-N 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229950009865 nafamostat Drugs 0.000 description 1
- MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000011301 petroleum pitch Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000008400 supply water Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 239000002441 uremic toxin Substances 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
Images
Landscapes
- External Artificial Organs (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002109647A JP4201313B2 (ja) | 2002-04-11 | 2002-04-11 | 有害物質結合アルブミン除去システム |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002109647A JP4201313B2 (ja) | 2002-04-11 | 2002-04-11 | 有害物質結合アルブミン除去システム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003299731A JP2003299731A (ja) | 2003-10-21 |
| JP2003299731A5 JP2003299731A5 (enrdf_load_stackoverflow) | 2005-09-15 |
| JP4201313B2 true JP4201313B2 (ja) | 2008-12-24 |
Family
ID=29393053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002109647A Expired - Lifetime JP4201313B2 (ja) | 2002-04-11 | 2002-04-11 | 有害物質結合アルブミン除去システム |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4201313B2 (enrdf_load_stackoverflow) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4843992B2 (ja) * | 2005-04-26 | 2011-12-21 | 東洋紡績株式会社 | 血液浄化器 |
| GB0621452D0 (en) | 2006-10-27 | 2006-12-06 | Ucl Business Plc | Therapy for liver disease |
| JP2010094266A (ja) * | 2008-10-16 | 2010-04-30 | Nipro Corp | 体外循環モジュールのプライミング用液体およびプライミング方法 |
| JP2014128451A (ja) * | 2012-12-28 | 2014-07-10 | Kawasumi Lab Inc | 血液浄化システム |
| JP2014161629A (ja) * | 2013-02-27 | 2014-09-08 | Kawasumi Lab Inc | 血液中のアディポネクチン上昇システム |
| GB202004775D0 (en) * | 2020-03-31 | 2020-05-13 | Ucl Business Ltd | Apparatus |
-
2002
- 2002-04-11 JP JP2002109647A patent/JP4201313B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003299731A (ja) | 2003-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2495459C (en) | Selective plasma exchange therapy | |
| US8038638B2 (en) | Plasma detoxification and volume control system and methods of use | |
| US5858238A (en) | Salvage of autologous blood via selective membrane/sorption technologies | |
| Fissell et al. | Achieving more frequent and longer dialysis for the majority: wearable dialysis and implantable artificial kidney devices | |
| KR102211104B1 (ko) | 혈액투석여과장치 | |
| Santoro et al. | Liver support systems | |
| US9138529B2 (en) | Anticoagulant-free dialysis systems and methods | |
| EP1765433B1 (en) | Plasma detoxification and volume control system | |
| EP0615780A1 (en) | Membrane and method for the separation of protein-bound substances from a protein-containing liquid by dialysis | |
| RU2086264C1 (ru) | Способ очистки крови при лечении больных, страдающих почечной недостаточностью и устройство для его осуществления | |
| US9950103B2 (en) | Combination kidney and liver dialysis system and method | |
| JP4201313B2 (ja) | 有害物質結合アルブミン除去システム | |
| JP2005506134A (ja) | 血漿搬出フィルターデバイスおよびアフェレーシス療法のための装置 | |
| EP1709982A1 (en) | Plasma exchange waste liquid purification circulation dialyzer | |
| de Francisco et al. | Hemodiafiltration with on-line endogenous reinfusion | |
| EP1002566B1 (en) | Filter for adsorbing heparin and/or endotoxins in plasma and/or blood | |
| EP2922585A1 (en) | Adsorbent for dialysis | |
| Lee et al. | Development of a multifunctional detoxifying unit for liver failure patients | |
| Vanholder et al. | Single needle haemodialysis | |
| ter Beek et al. | Advanced Blood Purification Therapies | |
| Faenzab | Liver Support Systems | |
| EP3024510A1 (en) | Blood purification systems and devices with internally generated replacement fluid | |
| Nosé et al. | Hepatic Assist 2: Devices for Use with Sorbents and Biological Reactors | |
| Nalesso et al. | Plasma Filtration Adsorption Dialysis: A New Experimental Approach to Treatment of Sepsis and MOF | |
| JP2006305306A (ja) | 血液浄化法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050401 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050401 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080410 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080609 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080704 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080828 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081006 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081006 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4201313 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111017 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111017 Year of fee payment: 3 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111017 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111017 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121017 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121017 Year of fee payment: 4 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121017 Year of fee payment: 4 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121017 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131017 Year of fee payment: 5 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| EXPY | Cancellation because of completion of term |